Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
US6638916B1 · kind B1 · utility
7Cited by
4References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 9, 2000 |
| Grant date | Oct 28, 2003 |
| Priority date | — |
| Expiry date | May 9, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for the inhibition of vascular smooth muscle cell hyperplasia in a human or other warm-blooded animal patient in need of such treatment, comprises administration to the patient of an effective amount of at least one sulfated oligosaccharide, wherein the oligosaccharide has the general formula I:R1—(Rx)n—R2  (I)wherein R1 and R2 and each Rx represents a monosaccharide unit, all of which may be the same or different, adjacent monosaccharide units being linked by 1→2, 1→3, 1→4 and/or 1→6 glycosidic bonds andn is an integer of from 1 to 6.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.